Drug labeling and exposure in neonates

JAMA Pediatrics

Volumn 168, Issue 2, 2014, Pages 130-136

  Laughon, Matthew M ^a   Avant, Debbie ^b   Tripathi, Nidhi ^c   Hornik, Christoph P ^c   Cohen Wolkowiez, Michael ^c   Clark, Reese H ^d   Smith, P Brian ^c   Rodriguez, William ^b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Departent of Pediatrix Analytical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; ANTIVIRUS AGENT; CARDIOVASCULAR AGENT; CASPOFUNGIN; DIDANOSINE; EMTRICITABINE; ESOMEPRAZOLE; GATIFLOXACIN; HIRULOG; LANSOPRAZOLE; LINEZOLID; LOPINAVIR PLUS RITONAVIR; MOXIFLOXACIN; NELFINAVIR; NEVIRAPINE; NITRIC OXIDE; PANTOPRAZOLE; PARACETAMOL; RANITIDINE; REMIFENTANIL; ROCURONIUM; SEVOFLURANE; SOTALOL; STAVUDINE; VALGANCICLOVIR;

ARTICLE; DRUG EFFICACY; DRUG EXPOSURE; DRUG LABELING; DRUG PACKAGING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HOSPITALIZED INFANT; HUMAN; LAW; MEDICAL LITERATURE; NEWBORN; NEWBORN INTENSIVE CARE; PRIORITY JOURNAL; UNITED STATES;

DRUG LABELING; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INTENSIVE CARE UNITS, NEONATAL; PEDIATRICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84893503265     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2013.4208     Document Type: Article

References (56)

1. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-1167.
2. Andersen DH, BlancWA, Crozier DN, Silverman WA. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics. 1956;18(4):614-625.
3. Stewart DJ. The effects of tetracyclines upon the dentition. Br J Dermatol. 1964;76:374-378.
4. Burns LE, Hodgman JE, Cass AB. Fatal circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med. 1959;261:1318-1321.
5. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics. 1998;101(5):7.
6. Aranda JV, Clarkson S, Collinge JM. Changing pattern of drug utilization in a neonatal intensive care unit. Am J Perinatol. 1983;1(1):28-30.
7. DuW,Warrier I, Tutag Lehr V, Salari V, Ostrea E, Aranda JV. Changing patterns of drug utilization in a neonatal intensive care population. Am J Perinatol. 2006;23(5):279-285.
8. Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C. The incidence of prescriptions without marketing product license in a neonatal intensive care unit [in French]. Arch Pediatr. 2000;7(2):143-147.
9. O'Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002;110(5):e52.
10. t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics. 2001;108(5):1089-1093.
11. US Food and Drug Administration Modernization Act. Pub LNo. 105-115, 111 Stat 2296 (1997).
12. Pediatric Rule. 21 CFR §31455
13. 21 CFR §60127
14. 21 CFR §201
15. 21 CFR §312
16. 21 CFR §314
17. 21 CFR §601. Code of Federal Regulations.
18. Best Pharmaceuticals for Children Act. Pub L No. 107-109, 115 Stat 1408 (2002).
19. Pediatric Research Equity Act. Pub L No. 108-155, 117 Stat 1936-1943 (2003).
20. US Food and Drug Administration Safety and Innovation Act of 2012. Pub L No. 112-114.
21. FDA Pediatric Labeling Changes Table. US Food and Drug Administration website. www.fda.gov. Accessed January 15, 2013.
22. Sachs AN, Avant D, Lee CS, RodriguezW, MurphyMD. Pediatric information in drug product labeling. JAMA. 2012;307(18):1914-1915.
23. Medical, Statistical, and Clinical Pharmacology Reviews of Pediatric Studies Conducted under Section 505A and 505B of the Federal Food, Drug, and Cosmetic Act (the Act), as amended by the FDA Amendments Act of 2007. US Food and Drug Administrationwebsite.www.fda.gov. Accessed January 15, 2013.
24. Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies Conducted under Section 505A and 505B of the Federal Food, Drug, and Cosmetic Act (the Act), as amended by the Best Pharmaceuticals for Children Act of 2002. US Food and Drug Administration website. www.fda.gov. Accessed January 15, 2013.
25. Drugs@FDA. US Food and Drug Administration website. http://www. accessdata.fda.gov/scripts /cder/drugsatfda/. Accessed June 11, 2013.
26. Standl T, Lochbuehler H, Galli C, Reich A, Dietrich G, Hagemann H. HES 130/0.4 (Voluven) or human albumin in children younger than 2 yr undergoing non-cardiac surgery: a prospective, randomized, open label, multicentre trial. Eur J Anaesthesiol. 2008;25(6):437-445.
27. Kovacs A, Cowles MK, Britto P, et al. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life. Pediatr Infect Dis J. 2005;24(6):503-509.
28. Omari T, Lundborg P, SandströmM, et al. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. J Pediatr. 2009;155(2):222-228.
29. James LP, Marotti T, Stowe CD, Farrar HC, Taylor BJ, Kearns GL. Pharmacokinetics and pharmacodynamics of famotidine in infants. J Clin Pharmacol. 1998;38(12):1089-1095.
30. Orenstein SR, Shalaby TM, Devandry SN, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther. 2003;17(9):1097-1107.
31. Moodley D, Pillay K, Naidoo K, et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin Pharmacol. 2001;41(7):732-741.
32. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178(5):1327-1333.
33. Springer M, Atkinson S, North J, Raanan M. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year. Paediatr Drugs. 2008;10(4):255-263.
34. ZhangW, Kukulka M, Witt G, Sutkowski-Markmann D, North J, Atkinson S. Age-dependent pharmacokinetics of lansoprazole in neonates and infants. Paediatr Drugs. 2008;10(4):265-274.
35. Kaplan SL, Deville JG, Yogev R, et al; Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant gram-positive infections in children. Pediatr Infect Dis J. 2003;22(8):677-686.
36. Kearns GL, Jungbluth GL, Abdel-Rahman SM, et al; Pediatric Pharmacology Research Unit Network. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther. 2003;74(5):413-422.
37. Chadwick EG, Pinto J, Yogev R, et al; International Maternal Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team. Early initiation of lopinavir/ritonavir in infants less than 6weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J. 2009;28(3):215-219.
38. Silver LH,Woodside AM, Montgomery DB. Clinical safety ofmoxifloxacin ophthalmic solution 0.5%(VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis. Surv Ophthalmol. 2005;50(suppl 1):S55-S63.
39. Bryson YJ,Mirochnick M, Stek A, et al; PACTG 353 Team. Pharmacokinetics and safety of nelfinavir when used in combinationwith zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials. 2008;9(2):115-125.
40. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL; PACTG 356 Investigators. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004;350(24):2471-2480.
41. Ballard RA, Truog WE, Cnaan A, et al; NO CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006;355(4):343-353.
42. Kinsella JP, Cutter GR,WalshWF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med. 2006;355(4):354-364.
43. Mercier JC, Hummler H, Durrmeyer X, et al; EUNO Study Group. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet. 2010;376(9738):346-354.
44. Ward RM, Tammara B, Sullivan SE, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur J Clin Pharmacol. 2010;66(6):555-561.
45. Wells TG, HeulittMJ, Taylor BJ, Fasules JW, Kearns GL. Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation. J Clin Pharmacol. 1998;38(5):402-407.
46. Davis PJ, Galinkin J,McGowan FX, et al. A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy, I: emergence and recovery profiles. Anesth Analg. 2001;93(6):1380-1386.
47. Galinkin JL, Davis PJ, McGowan FX, et al. A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy, II: perioperative breathing patterns in neonates and infantswith pyloric stenosis. Anesth Analg. 2001;93(6):1387-1392.
48. Russell IA, Miller HanceWC, Gregory G, et al. The safety and efficacy of sevoflurane anesthesia in infants and children with congenital heart disease. Anesth Analg. 2001;92(5):1152-1158.
49. Saul JP, Ross B, SchafferMS, et al; Pediatric Sotalol Investigators. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. Clin Pharmacol Ther. 2001;69(3):145-157.
50. Saul JP, SchafferMS, Karpawich PP, et al. Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia. J Clin Pharmacol. 2001;41(1):35-43.
51. Shi J, Ludden TM, Melikian AP, GastonguayMR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. J Pharmacokinet Pharmacodyn. 2001;28(6):555-575.
52. Rongkavilit C, Thaithumyanon P, ChuenyamT, et al. Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates. Antimicrob Agents Chemother. 2001;45(12):3585-3590.
53. Kimberlin DW, Acosta EP, Sánchez PJ, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008;197(6):836-845.
54. Laughon MM, Benjamin DK Jr, Capparelli EV, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol. 2011;4(5):643-652.
55. MalcolmWF, Cotten CM.Metoclopramide, H2 blockers, and proton pump inhibitors: pharmacotherapy for gastroesophageal reflux in neonates. Clin Perinatol. 2012;39(1):99-109.
56. Cole FS, Alleyne C, Barks JD, et al. NIH consensus development conference: inhaled nitric oxide therapy for premature infants. NIH Consens State Sci Statements. 2010;27(5):1-34.